CN114509513B - Liquid chromatography high-resolution mass spectrometry qualitative and quantitative detection method for bile acid in multiple tissues - Google Patents
Liquid chromatography high-resolution mass spectrometry qualitative and quantitative detection method for bile acid in multiple tissues Download PDFInfo
- Publication number
- CN114509513B CN114509513B CN202111636454.4A CN202111636454A CN114509513B CN 114509513 B CN114509513 B CN 114509513B CN 202111636454 A CN202111636454 A CN 202111636454A CN 114509513 B CN114509513 B CN 114509513B
- Authority
- CN
- China
- Prior art keywords
- liquid chromatography
- mass spectrometry
- solution
- bile acid
- bile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/045—Standards internal
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The invention belongs to the field of pharmaceutical analysis, and particularly relates to a qualitative and quantitative detection method for bile acid in multiple tissues by using liquid chromatography and high-resolution mass spectrometry. The detection method comprises the following steps: preparing a mixed internal standard working solution and a standard solution, pretreating a bile acid sample to be detected, and then performing liquid chromatography mass spectrometry, wherein the mobile phase A is 0.05-0.2% formic acid water and the mobile phase B is 0.05-0.2% formic acid acetonitrile in the liquid chromatography conditions, gradient elution is adopted, the flow rate is 350 mul/min, and the column temperature is 35-45 ℃. The mass spectrometry conditions are that an electrospray ion source is adopted, negative ion scanning is carried out, and the pressure of an atomizer is 48-52psi; collision energy 58-62V; the capillary voltage is 5.2-5.7kV; the ion temperature is 590-610 ℃; the mass range m/z is 50-800Da. The invention establishes a qualitative and quantitative detection method for bile acid in various tissues, can realize qualitative and quantitative detection of various bile acid in various animal tissues such as fish, mice and the like or medicinal materials such as arisaema cum bile and the like, and has the advantages of simple method, simple reagent and sensitive detection.
Description
Technical Field
The invention belongs to the field of pharmaceutical analysis, and particularly relates to a qualitative and quantitative detection method for bile acid in multiple tissues by using liquid chromatography and high-resolution mass spectrometry.
Background
BAs are amphiphilic sterol molecules synthesized from cholesterol in the liver, which are excreted into bile as one of the major components of bile. BAs (amino acid-acyl-binding primary bile acids, cholic acid [ CA ], chenodeoxycholic acid [ CDCA ] and their secondary metabolites) are secreted by hepatic parenchymal cells into the tubules, which are the main driving force for bile acid production. The BAs, along with other bile components, all flow into the small intestine, acting to emulsify and absorb fat, cholesterol, and fat-soluble vitamins. Upon reaching the terminal ileum, the BAs are almost completely (95%) absorbed by the active absorption mechanism, and the BAs, which are about as they are lost in the stool, are balanced by the daily synthetic BAs. In the distal small intestine and colon, primary BAs (CA and CDCA) are often bacterially de-bound and dehydroxylated to form secondary BAs (i.e., deoxycholic acid [ DCA ] and lithocholic acid [ LCA ]). These secondary BAs can be passively reabsorbed and form part of the total bile acid pool of the hepatic-intestinal circulation.
For many years, it has been believed that the function of BAs has been largely limited to stimulating hepatic bile flow and bile excretion, and to assisting in the digestion and absorption of fat from the intestinal lumen. However, research over the past two decades has recognized that BAs may act as signaling molecules through various receptors to regulate their synthesis and other metabolic processes such as glucose, lipid, energy homeostasis.
The regulation of BAs is mediated through specific BA-activating receptors, including members of the nuclear receptor superfamily (farnesoid X receptors [ FXR; NR1H4], vitamin D receptors [ NR 1I1] and pregnane X receptors [ N R1I2], as well as members of the G protein-coupled receptor superfamily (TGR 5 and sphingosine-1-phosphate receptor 2). The receptors are expressed by tissues of the gastrointestinal circulation and are not limited to the liver and the gastrointestinal system, where they regulate the systemic action of BAs.
As an endogenous metabolite, bile acid has various types, and shows diversified and even opposite biochemical and physiological characteristics due to different side chain structures, stereochemistry properties, number and positions of hydroxyl groups, and the like, at present, related researches are mainly carried out by detecting serum total bile acid levels, and wrong judgment is easily caused due to poor sensitivity and specificity. Therefore, the method can help us to analyze and research the whole physiological and biochemical process of the organism by comprehensively and accurately monitoring the content of various types of bile acid in the biological sample.
The Chinese patent application CN109030676A discloses a tandem mass spectrometry detection kit for simultaneously determining 16 bile acids and application thereof, comprising a standard substance, a quality control substance, an internal standard substance, a precipitator, a diluent and a mobile phase, wherein the diluent consists of water, methanol, ethanol and acetonitrile, the volume ratio of the water, the methanol, the ethanol and the acetonitrile is 1-50; the mobile phase comprises a mobile phase A and a mobile phase B, wherein the mobile phase A is an aqueous solution of ammonium formate or ammonium acetate-formic acid or acetic acid, and the mobile phase B is methanol and/or acetonitrile. The disadvantages of this method include the following: 1, the pretreatment process is complicated, various reagents are used, and the time is long. 2, the number of bile acids detected is small and some important bile acids are lacking.
The existing qualitative and quantitative method for bile acid mainly has the following defects that on one hand, the types of the quantifiable bile acid are few, the quantifiable bile acid is mainly four kinds of free bile acid, namely Cholic Acid (CA), deoxycholic acid (DCA), chenodeoxycholic acid (CDCA) and a small amount of lithocholic acid (LCA), and the used method is basically low-resolution mass spectrum, such as liquid chromatography tandem triple quadrupole mass spectrum and the like; on the other hand, serum is usually selected as a biological sample for the quantification of bile acid, but the methods for extracting and detecting bile acid from other tissue samples such as bile and liver are less involved, the distribution of the bile acid in different tissues is different, the interference of matrixes of different tissues in the analysis and detection process is different, and the blood analysis method cannot cover all the tissues. Due to the continuous discovery of the function of bile acid, the establishment of a method for simultaneously qualitatively and quantitatively analyzing and detecting multiple kinds of bile acid in each part of tissues of an organism by high resolution mass spectrometry is necessary and urgently needed.
Disclosure of Invention
Aiming at the defects in the prior art, the invention establishes a qualitative and quantitative detection method for bile acid in various tissues, the method can realize qualitative and quantitative detection of various bile acid in various tissues of animals such as fish, mice and the like or medicinal materials such as arisaema cum bile and the like, and the method is simple, the reagent is simple, and the detection is sensitive.
In order to realize the purpose of the invention, the technical scheme is as follows:
a liquid chromatography mass spectrometry detection method of bile acid in multiple tissues comprises performing liquid chromatography mass spectrometry on a bile acid sample to be detected, wherein in the liquid chromatography condition, a mobile phase A is 0.05-0.2% formic acid water, a mobile phase B is 0.05-0.2% formic acid acetonitrile,
the gradient elution procedure was as follows:
0min,A:B(74-76:24-26,V/V);
4min,A:B(74-76:24-26,V/V);
16min,A:B(58-62:38-42,V/V);
30min,A:B(24-26:74-76,V/V);
31min,A:B(0-2:98-100,V/V);
33min,A:B(0-2:98-100,V/V);
the flow rate is 340-360 mul/min, and the column temperature is 35-45 ℃.
Preferably, the conditions of mass spectrometry comprise: adopting an electrospray ion source, scanning negative ions, and controlling the pressure of an atomizer to be 48-52psi; collision energy 58-62V; the capillary voltage is 5.2-5.7kV; the ion temperature is 590-610 ℃; the mass range m/z is 50-800Da.
Preferably, the sample amount in the liquid chromatography condition is 2-5 μ L, the chromatographic column is a C-octadecyl filler chromatographic column, and the C-octadecyl filler chromatographic column is an ACQUITYUPLC BEH C18 (1.7 μm, 2.1X 150 mm) chromatographic column.
Preferably, the detection method further comprises the preparation of a mixed internal standard working solution, and specifically comprises the step of adding methanol into CA-D4, CDCA-D4 and LCA-D4 to prepare the mixed internal standard working solution with the concentration of each component being 4-6 mu g/ml respectively.
Preferably, the detection method further comprises the preparation of a standard solution, specifically comprising: preparing HCA, omega MCA, alpha MCA, T alpha MCA, beta MCA, CDCA, DCA, UDCA, HDCA, 6,7-KLCA, 7,12-KLCA, T beta MCA, T omega MCA, THDCA, TUDCA, GCA, GCDCA, GDCA, GUDCA, LCA, 7-KLCA and 12-KLCA into a standard solution 1 with the concentration of each component being 2-320ng/ml respectively; adding methanol into TCA, TCDCA, CA and TDCA to obtain standard solution 2 with concentration of 10-800 ng/ml.
Preferably, the detection method further comprises a pretreatment step of a bile acid sample to be detected, and when the bile acid sample to be detected is a solid tissue, the pretreatment step comprises: adding the mixed internal standard working solution into the solid tissue, adding 70-80% ethanol solution, crushing, centrifuging, taking supernatant 1, adding glacial acetonitrile, centrifuging for the second time, and taking supernatant 2 to obtain the final product.
Preferably, the mass-to-volume ratio of the solid tissue to the 70-80% ethanol solution is 90-110mg/ml, and the crushing is uniform by intense shaking by a sample crushing system.
Preferably, the volume ratio of the supernatant 1 to the glacial acetonitrile is 48-52:48-52.
Preferably, when the bile acid sample to be detected is bile, the pretreatment step includes: adding 75-85% methanol water solution into bile, standing at-18 deg.C to-22 deg.C, centrifuging to obtain supernatant 3, adding 15-45% methanol solution and mixed internal standard working solution, centrifuging again, and collecting supernatant 4.
Preferably, the volume ratio of the bile to 75-85% methanol aqueous solution is 1;
preferably, the standing time is 25-35min.
Preferably, the volume ratio of the supernatant 3 to the 15-45% methanol solution and the mixed internal standard working solution is 38-42.
Preferably, the temperature of the centrifugation or the secondary centrifugation is 2-5 ℃, the rotating speed is 12000-18000rpm, and the time is 5-15min.
Preferably, when the bile acid sample to be detected is a plasma sample, the pretreatment step includes: adding the mixed internal standard solution into the plasma, mixing, adding 70-80% ethanol water solution, centrifuging, collecting supernatant, performing C18 solid phase extraction, eluting with 45-55% methanol solution, discarding, eluting with triethylamine-water-methanol mixed solution system, and collecting eluate.
Preferably, the volume ratio of the blood plasma to the 70-80% ethanol water solution is 1.
Preferably, before the extraction, the solid phase C18 is activated by acetonitrile and 3% formic acid solution in a mass ratio of 1.8-1.2.
Preferably, the volume ratio of triethylamine to water to methanol is 1-3.
The invention further aims to provide the application of the liquid chromatography-mass spectrometry detection method in qualitative or quantitative detection of various bile acids in animal tissues or traditional Chinese medicines. Compared with the prior art, the invention has the beneficial effects that:
(1) The method can be used for simultaneously carrying out qualitative and quantitative analysis on at least 26 bile acids with different structural types in different tissues, and has the advantages of good separation effect and higher detection result accuracy.
(2) The method can detect the bile acid content of different tissues of the animal, and the sample processing method is rapid, and the method adopts methanol with certain concentration to extract and purify the bile acid in the bile, so that the method is more favorable for subsequent on-machine detection compared with the method adopting chloroform and the like to uniformly mix and stratify; when the plasma sample is pretreated, a certain amount of triethylamine and water are added into the eluent to be compatible with methanol, so that bile acid compounds in the plasma can obtain better impurity removal and separation effects, and later detection is facilitated.
(3) In the detection method, all bile acid is well separated and responded, the quantification limit of the bile acid can reach 2ng/ml or even lower, and a good linear relation is presented in the concentration range of 2-320 ng/ml.
Drawings
FIG. 1 is an ion flow diagram of bile acid detection of a fish plasma sample of example 4.
FIG. 2 is an ion flow diagram of the detection of HCA, beta MCA, CDCA, DCA, UDCA, HDCA, 6,7-KLCA, 7,12-KLCA, T beta MCA, T omega MCA, THDCA, TUDCA, GCA, GCDCA, GDCA, GUDCA, LCA, 7-KLCA, 12-KLCA in mixed standard solutions.
FIG. 3 is an ion flow diagram of ω MCA, α MCA, and T α MCA in a mixed standard solution.
FIG. 4 is an ion flow diagram of TCA, TCDCA, CA, TDCA in a mixed standard solution.
Fig. 5 is an ion flow diagram for the test of comparative example 1.
Fig. 6 is an ion flow diagram of the test of comparative example 2.
Detailed Description
The present invention will be further described with reference to the following embodiments.
The mixed internal standard solutions in the following examples were prepared as follows:
respectively weighing 10mg of reference substances CA-D4, CDCA-D4 and LCA-D4, and dissolving in 10ml of methanol to obtain 1mg/ml of standard mother liquor.
Respectively sucking 50 mul of CA-D4, CDCA-D4, LCA-D4 standard substance mother liquor and 50 mul of methanol, fully mixing to prepare 50 mul/ml high-concentration mixed standard solution, and gradually diluting with 50% methanol solution to prepare 5 mul/ml mixed internal standard working solution.
EXAMPLE 1 pretreatment of solid samples of whole fish
The live fish is anesthetized in the fish calming process, placed at minus 80 ℃ for 10min, taken out, cut into small pieces, placed at minus 80 ℃ until being completely frozen, freeze-dried by a freeze dryer, and fully and uniformly crushed by a high-speed universal crusher until bile acid is extracted after complete drying.
Accurately weighing 100mg of processed sample into a 2ml centrifuge tube, adding 20 mul of mixed internal standard solution with the concentration of 5 mul g/ml, adding 980 mul of extracting solution which is 75% ethanol solution, then violently shaking for 3min by using a vortex oscillator to fully extract bile acid, after shaking uniformly, centrifuging for 10min (15000rpm, 4 ℃), taking 500 mul of supernatant into a new 2ml centrifuge tube, adding 500 mul of glacial acetonitrile, centrifuging for 10min under the same conditions after vortex mixing uniformly, taking supernatant to pass through a 0.2 mu m filter membrane to an automatic sample feeding bottle, and detecting by using a machine.
Example 2 pretreatment of solid samples liver, gut content and parotid gland
Preparing a clean mortar, enough liquid nitrogen and about 200mg of frozen samples of liver, intestinal tract and intestinal tract contents or parotid gland tissues, fully grinding the frozen samples, and waiting for extracting bile acid.
Accurately weighing 100mg of processed sample into a 2ml centrifuge tube, adding 20 mul of mixed internal standard solution with the concentration of 5 mul g/ml, adding 980 mul of extracting solution which is 75% ethanol solution, then violently shaking for 3min by using a vortex oscillator to fully extract bile acid, centrifuging for 10min (15000rpm, 4 ℃) after even shaking, taking 500 mul of supernatant to a new 2ml centrifuge tube, adding 500 mul of pre-cooled glacial acetonitrile, centrifuging for 10min under the same conditions after even vortex mixing, taking the supernatant, passing through a 0.2 mu m filter membrane to an automatic sample feeding bottle, and waiting for detection by a computer.
EXAMPLE 3 pretreatment of liquid sample bile
Taking the gall bladder out of a refrigerator at minus 80 ℃, thawing the gall bladder on ice, taking 5 mu l of bile into a 2ml centrifuge tube, adding 1995 mu l of 80% methanol water solution, uniformly vortexing, standing at minus 20 ℃ for 30min, centrifuging for 10min (15000rpm, 4 ℃), taking 400 mu l of supernatant into a new 2ml centrifuge tube, adding 600 mu l of 30% methanol solution and 10 mu l of mixed internal standard solution with the concentration of 5 mu g/ml, vortexing for 1min, passing through a 0.2 mu m filter membrane to an automatic sample feeding bottle, and waiting for detection on a machine.
EXAMPLE 4 Pre-treatment of liquid sample plasma
Thawing fish plasma on ice, collecting 100 μ l plasma into 2ml centrifuge tube, adding 10 μ l 1 μ g/ml mixed internal standard solution, mixing, adding 890 μ l 75% ethanol water solution, vortex for 1min, and storing in 4 deg.C refrigerator for use. Adopting a C18 needle type solid phase extraction filter to purify a plasma sample, wherein the plasma purification process comprises the following steps:
and (3) activation: 2ml acetonitrile, 2ml 3% formic acid water
Loading: 1ml of the above plasma sample
Leaching: 1ml 50% methanol solution, discarding the eluate
And (3) elution: 2ml triethylamine-water-methanol (2% -18% -80%)
Mixing and collecting eluate, blowing the solvent under nitrogen flow, re-dissolving with 200 μ l 75% ethanol solution, filtering with 0.2 μm filter membrane to automatic sampling bottle, and detecting with computer.
EXAMPLE 5 high Performance liquid chromatography-Mass Spectrometry analysis of sample bile acids
Examples 1-4 samples were pretreated and analyzed by HPLC-MS:
an ACQUITY UPLC BEH C18 (1.7. Mu. 2.1X 150 mm) column was used with mobile phases A0.1% formic acid water and B0.1% formic acid acetonitrile. The gradient elution procedure is shown in table 1 below:
TABLE 1 gradient elution schedule
The flow rate was 350. Mu.l/min. The column temperature was 40 ℃ and the injection volume was 3. Mu.L.
Mass spectrum detection and analysis: Q-TOF detection (SCIEX, USA) was electrospray ionization (ESI) performed in negative ion mode with nebulizer pressure of 50psi; collision energy 60V; capillary voltage 5.5kV; the ion temperature is 600 ℃; the mass range m/z is 50-800Da.
On the basis of this method, all bile acids are well separated and responded. The analytical chromatogram of example 4 is shown in FIG. 1.
The invention determines the lowest quantitative limit and linear range of each component according to the 2020 version Chinese pharmacopoeia quality analysis methodology, and the results are shown in the following table 2.
The standard solutions in the linear assay were prepared as follows:
(1) 10mg of reference substances TCA, TCDCA, CA, TDCA, HCA, beta MCA, alpha MCA, T alpha MCA, CDCA, DCA, UDCA, HDCA, 6,7-KLCA, 7,12-KLCA, T beta MCA, T omega MCA, THDCA, TUDCA, GCA, GCDCA, GDCA, GUDCA, LCA, 7-KLCA, 12-KLCA, CA-D4, CDCA-D4 and LCA-D4 are respectively weighed, and 10ml of methanol is added to dissolve the reference substances to prepare 1mg/ml of standard mother solution.
50 mul of HCA, omega MCA, beta MCA, alpha MCA, T alpha MCA, CDCA, DCA, UDCA, HDCA, 6,7-KLCA, 7,12-KLCA, T beta MCA, T omega MCA, THDCA, TUDCA, GCA, GCDCA, GDCA, GUDCA, LCA, 7-KLCA, 12-KLCA standard mother liquor and 50 mul of methanol are respectively sucked and fully mixed to prepare a high-concentration mixed standard solution of 50 mul/ml, and then the mixed standard solution is gradually diluted to the standard working solution 1 of 320, 160, 80, 40, 20, 10 and 2ng/ml by using 50 percent methanol solution. 80ng/ml of the standard working solution 1 was analyzed according to the HPLC-MS method of example 5, as shown in FIGS. 2 to 3.
Respectively sucking 50 mul of TCA, TCDCA, CA, TDCA standard substance mother liquor and 50 mul of methanol, fully mixing to prepare 50 mul/ml high-concentration mixed standard solution, and gradually diluting to 800, 400, 200, 100, 50, 25 and 10ng/ml standard working solution 2 by using 50% methanol solution. Standard working solution 1 at 200ng/ml was analyzed according to the HPLC-MS method of example 5, as shown in FIG. 4.
TABLE 2 detection, quantitation and Linear Range of different bile acids
Comparative example 1
This comparative example is a different gradient elution procedure than example 5, as shown in table 3 below. The detection chromatogram of the mixed standard solution is shown in FIG. 5.
TABLE 3 gradient elution schedule
Comparative example 2
In comparison with example 5, the mobile phase A is 0.1% formic acid water, the mobile phase B is acetonitrile, the flow rate is 0.5ml/min, the column temperature is 55 ℃, all the reference substances have peaks in 10min, the overlapping interference exists among a plurality of chromatographic peaks, and the detected chromatographic ion flow diagram is shown in FIG. 6.
The above detailed description is directed to one of the possible embodiments of the present invention, which is not intended to limit the scope of the invention, but rather the scope of the invention is intended to include all equivalent implementations or modifications without departing from the scope of the invention.
Claims (11)
1. A liquid chromatography mass spectrometry detection method of bile acid in multiple tissues is characterized by comprising the following steps of liquid chromatography mass spectrometry analysis, wherein the mobile phase A in the liquid chromatography condition is 0.05-0.2% of formic acid water, the mobile phase B in the liquid chromatography condition is 0.05-0.2% of formic acid acetonitrile,
the gradient elution procedure was as follows:
0min,A:B,74-76:24-26,V/V;
4 min,A:B,74-76:24-26,V/V;
16 min,A:B,58-62:38-42,V/V;
30 min,A:B,24-26:74-76,V/V;
31 min,A:B,0-2:98-100,V/V;
33 min,A:B,0-2:98-100,V/V;
the flow rate is 340-360 mul/min, and the column temperature is 35-45 ℃;
when the bile acid sample to be detected is a plasma sample, the pretreatment steps comprise: adding the mixed internal standard solution into the plasma, mixing, adding 70-80% ethanol water solution, centrifuging, collecting supernatant, performing C18 solid phase extraction, eluting with 45-55% methanol solution, discarding, eluting with triethylamine-water-methanol mixed solution system, and collecting eluate;
the chromatographic column is an ACQUITY UPLC BEH C18 chromatographic column;
the detection method also comprises the preparation of a standard solution, and concretely comprises the steps of preparing a standard solution 1 with the concentration of each component of 2-320ng/ml by adding methanol into HCA, omega MCA, alpha MCA, T alpha MCA, beta MCA, CDCA, DCA, UDCA, HDCA, 6,7-KLCA, 7,12-KLCA, T beta MCA, T omega MCA, THDCA, TUDCA, GCA, GCDCA, GDCA, GUDCA, LCA, 7-KLCA and 12-KLCA; adding methanol into TCA, TCDCA, CA and TDCA to prepare standard solution 2 with concentration of each component of 10-800 ng/ml.
2. The liquid chromatography mass spectrometry detection method of claim 1, wherein the conditions of the mass spectrometry analysis comprise: adopting an electrospray ion source, scanning negative ions, and controlling the pressure of an atomizer to be 48-52psi; collision energy 58-62V; the capillary voltage is 5.2-5.7kV; the ion temperature is 590-610 ℃; the mass range m/z is 50-800Da.
3. The method for detecting the liquid chromatography mass spectrometry according to claim 1, wherein the sample size in the liquid chromatography condition is 2-5 μ L.
4. The method for liquid chromatography mass spectrometry detection according to claim 1, further comprising the preparation of a mixed internal standard working solution, specifically comprising: and adding methanol into the CA-D4, the CDCA-D4 and the LCA-D4 to prepare mixed internal standard working solution with the concentration of each component being 4-6 mu g/ml respectively.
5. The liquid chromatography-mass spectrometry detection method of claim 1, further comprising a pretreatment step of a bile acid sample to be detected, wherein when the bile acid sample to be detected is a solid tissue, the pretreatment step comprises: adding the mixed internal standard working solution into the solid tissue, adding 70-80% ethanol solution, crushing, centrifuging, taking supernatant 1, adding glacial acetonitrile, centrifuging for the second time, and taking supernatant 2 to obtain the final product.
6. The method for detecting the liquid chromatography mass spectrometry according to claim 5, wherein the mass-to-volume ratio of the solid tissue to the 70-80% ethanol solution is 90-110mg/ml, and the crushing is uniform by intense shaking by a sample crushing system; the volume ratio of the supernatant 1 to the glacial acetonitrile is 48-52:48-52.
7. The liquid chromatography mass spectrometry detection method of claim 5, wherein when the bile acid sample to be detected is bile, the pretreatment step comprises: adding 75-85% methanol water solution into bile, standing at-18 deg.C to-22 deg.C, centrifuging to obtain supernatant 3, adding 15-45% methanol solution and mixed internal standard working solution, centrifuging again, and collecting supernatant 4.
8. The liquid chromatography mass spectrometry detection method of claim 7, wherein the volume ratio of the bile to 75-85% methanol aqueous solution is 1.
9. The method for detecting liquid chromatography mass spectrometry according to claim 5 or 7, wherein the temperature of the centrifugation or the secondary centrifugation is 2-5 ℃, the rotation speed is 12000-18000rpm, and the time is 5-15min.
10. The method for liquid chromatography mass spectrometry detection according to claim 1, wherein the volume ratio of the plasma to 70-80% ethanol aqueous solution is 1.
11. Use of a liquid chromatography mass spectrometry detection method according to any one of claims 1 to 10 for the qualitative or quantitative detection of multiple bile acids in animal tissue.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111636454.4A CN114509513B (en) | 2021-12-29 | 2021-12-29 | Liquid chromatography high-resolution mass spectrometry qualitative and quantitative detection method for bile acid in multiple tissues |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111636454.4A CN114509513B (en) | 2021-12-29 | 2021-12-29 | Liquid chromatography high-resolution mass spectrometry qualitative and quantitative detection method for bile acid in multiple tissues |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114509513A CN114509513A (en) | 2022-05-17 |
CN114509513B true CN114509513B (en) | 2022-11-15 |
Family
ID=81548693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111636454.4A Active CN114509513B (en) | 2021-12-29 | 2021-12-29 | Liquid chromatography high-resolution mass spectrometry qualitative and quantitative detection method for bile acid in multiple tissues |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114509513B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116183780A (en) * | 2023-04-25 | 2023-05-30 | 天津云检医学检验所有限公司 | Absolute quantitative analysis method for bile acid in serum sample |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6082328B2 (en) * | 2013-07-31 | 2017-02-15 | 株式会社Lsiメディエンス | Bile acid simultaneous analysis method |
CN110596295A (en) * | 2019-10-21 | 2019-12-20 | 上海百趣生物医学科技有限公司 | Method for detecting bile acid |
AU2021254287A1 (en) * | 2020-04-09 | 2022-11-10 | HepQuant, LLC | Improved methods for evaluating liver function |
-
2021
- 2021-12-29 CN CN202111636454.4A patent/CN114509513B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN114509513A (en) | 2022-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6082328B2 (en) | Bile acid simultaneous analysis method | |
Noppe et al. | Novel analytical methods for the determination of steroid hormones in edible matrices | |
CN110187043A (en) | Method that is a kind of while detecting 13 kinds of steroid hormones in serum | |
US8470602B2 (en) | Methods and systems for determining the presence or amount of delta 5 steroid compounds in a sample | |
Bentayeb et al. | Determination of bile acids in human serum by on-line restricted access material–ultra high-performance liquid chromatography–mass spectrometry | |
CN107843671A (en) | A kind of detection method of the high flux Liquid Chromatography-Tandem Mass Spectrometry of high flux Liquid Chromatography-Tandem Mass Spectrometry | |
CN109239224B (en) | Method for simultaneously and quantitatively measuring 9 blood-entering components in spina date seed water extract | |
WO2022252443A1 (en) | Method for qualitatively analyzing phospholipid components in platycodon grandiflorum and performing c=c localization on phospholipid components in platycodon grandiflorum | |
CN114509513B (en) | Liquid chromatography high-resolution mass spectrometry qualitative and quantitative detection method for bile acid in multiple tissues | |
CN104198609B (en) | The method of the compound with pregnane mother nucleus structure is extracted from composition | |
CN111474256A (en) | HP L C-MSMS-based quantitative analysis method for bile acid in feces | |
CN111665308A (en) | Kit for detecting 15 bile acids in serum and application thereof | |
CN112098532A (en) | Improved detection method for 15 bile acids in human serum by high performance liquid chromatography tandem mass spectrometry | |
CN111141854A (en) | Method for simultaneously extracting polar and low-polar metabolites from biological sample | |
CN112986433A (en) | Method for detecting steroid content in human serum sample | |
WO2022049726A1 (en) | Analysis method and analysis system for bile acids, sterols, and hormones | |
CN112666291A (en) | Bile acid detection method based on high-throughput liquid chromatography-mass spectrometry combined technology | |
Zhang et al. | Rapid identification of bile acids in snake bile using ultrahigh-performance liquid chromatography with electrospray ionization quadrupole time-of-flight tandem mass spectrometry | |
CN116124969B (en) | LC-MS/MS kit for simultaneously extracting and measuring PCOS related twelve steroid hormones in serum | |
CN112505187A (en) | Method for detecting bile acid in excrement by UPLC-MS/MS (ultra Performance liquid chromatography-Mass Spectrometry/Mass Spectrometry) combination | |
CN109212065A (en) | The detection method of cholesterol metabolin in a kind of brain tissue | |
CN115290764B (en) | Method for simultaneously detecting 10 kinds of hormone residues in edible tissues of cattle and sheep by UPLC-MS/MS | |
CN112285243A (en) | Treatment method for detecting drug residues in animal tissue sample, confirmation detection method and application thereof | |
CN112198251A (en) | Method for detecting concentration of six bufadienolide components in medicinal preparation containing cutis Bufonis in blood plasma or tissue | |
Yang et al. | Determination of selected glucocorticoids in healthy foods by ultra-performance convergence chromatography–triple quadrupole mass spectrometry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |